Skip to content

The Effect of Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed With Generalized Anxiety Disorder on Cognitive Avoidance Levels and Coping Attitudes

The Effect of Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed With Generalized Anxiety Disorder on Cognitive Avoidance Levels and Coping Attitudes

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06972563
Enrollment
60
Registered
2025-05-15
Start date
2024-06-25
Completion date
2025-06-25
Last updated
2025-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Keywords

Generalized Anxiety Disorder, Acceptance and Commitment Therapy, Cognitive Avoidance, Coping Attitudes

Brief summary

This study will be conducted to determine the effects of acceptance and commitment therapy-based psychoeducation on cognitive avoidance levels and coping attitudes in patients diagnosed with generalized anxiety disorder. H0: Acceptance and commitment therapy-based psychoeducation has no effect on the cognitive avoidance levels and coping attitudes of patients diagnosed with generalized anxiety disorder. H1: Acceptance and commitment therapy-based psychoeducation reduces the cognitive avoidance levels of patients diagnosed with generalized anxiety disorder. H2: Acceptance and commitment therapy-based psychoeducation affects the coping attitudes of patients diagnosed with generalized anxiety disorder.

Interventions

OTHERPsychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder

Psychoeducation Based on Acceptance and Commitment Therapy Applied to Patients Diagnosed with Generalized Anxiety Disorder

OTHERThe initiative was not implemented.

The initiative was not implemented.

Sponsors

Arzu Çalışkan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Having been diagnosed with generalized anxiety disorder according to DSM-5 diagnostic criteria and receiving outpatient treatment * Being literate * Having no problems understanding or speaking Turkish * Being in the 18-65 age group * Having not received such training in the last 6 months

Exclusion criteria

* Those diagnosed with another comorbid mental illness Patients with a mental condition that makes cooperation impossible, such as intellectual disability or memory impairment * The illiterate * Patients who do not consent to be interviewed

Design outcomes

Primary

MeasureTime frameDescription
Measuring the effect of cognitive avoidance levels of patients diagnosed with generalized anxiety disorder1 monthPatients answered cognitive avoidance scale. Cognitive Avoidance Scale (Cope) measures cognitive avoidance strategies. COA is a self-assessment type scale. The five (1-5) point Likert-type scale (1-strongly disagree, 5-strongly agree) measures 25 items of COA. The score that can be obtained from the scale is between 12 and 125. In order to calculate the total score, it is necessary to sum the answers given to all items. A high score indicates that a cognitive avoidance strategy is used in the face of problems.

Secondary

MeasureTime frameDescription
coping attitudes of patients diagnosed with generalized anxiety disorder1 monthThe scale is a 4-point Likert-type scale. When scoring the items, 1 point is given for I Never Do This, 2 points for I Rarely Do This, 3 points for I Do This and 4 points for I Often Do This. There are no negative items in the scale. The highest score that can be obtained from the scale is 160, the lowest score is 40. A high score obtained from the scale means a high level of coping attitude, and a low score means a low level of coping attitude.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026